{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:02:30Z","timestamp":1781244150965,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NHS"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ejca.2013.05.008","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T08:16:31Z","timestamp":1371716191000},"page":"2815-2822","source":"Crossref","is-referenced-by-count":35,"title":["Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct00458913","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mary E.R.","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab M.","family":"Gaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis C.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Cufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ottensmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Pallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baktiar","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.05.008_b0005","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2005.05.1359","article-title":"Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma \u2013 the EORTC Lung Cancer Group","volume":"24","author":"Francart","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.05.008_b0010","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.05.008_b0015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/JTO.0b013e31824ab6c5","article-title":"Pleurectomy\/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma","volume":"7","author":"Lang-Lazdunski","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2013.05.008_b0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1586\/era.10.169","article-title":"Malignant pleural mesothelioma: when is radiation therapy indicated?","volume":"11","author":"van Thiel","year":"2011","journal-title":"Expert Rev Anticanc"},{"key":"10.1016\/j.ejca.2013.05.008_b0025","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.ejca.2011.05.012","article-title":"Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma","volume":"47","author":"Jenkins","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2013.05.008_b0030","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.05.008_b0035","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.05.008_b0040","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.05.008_b0045","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2013.05.008_b0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00280-009-1181-8","article-title":"Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines","volume":"66","author":"Wang","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2013.05.008_b0055","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1158\/1078-0432.CCR-07-0536","article-title":"Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma","volume":"13","author":"Sartore-Bianchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.05.008_b0060","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"Fennell","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2013.05.008_b0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.05.008_b0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2013.05.008_b0075","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use. Guideline for good clinical practice E6(R1), 1996. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1_Guideline.pdf."},{"key":"10.1016\/j.ejca.2013.05.008_b0080","unstructured":"Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, 2003. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3pdf."},{"key":"10.1016\/j.ejca.2013.05.008_b0085","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.2517-6161.1976.tb01597.x","article-title":"The empirical distribution function with arbitrarily grouped, censored and truncated data","volume":"38","author":"Turnbull","year":"1976","journal-title":"JRSS-B"},{"key":"10.1016\/j.ejca.2013.05.008_b0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491300405X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491300405X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T17:16:00Z","timestamp":1715534160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491300405X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":18,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S095980491300405X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.05.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}